

Supporting Buyer Uptake of Effective FMD Vaccines in Eastern Africa

© Shutterstock/Dineshahir

A Dual Threat to Trade and Animal Health

As one of the most infectious livestock diseases in the world, Foot and Mouth Disease (FMD) presents a constant global threat to animal trade and national economies. Endemic throughout Eastern Africa, FMD can devastate livestock productivity and severely compromise small-scale farmers' livelihoods and food security. Vaccination is proven to effectively control FMD, but current vaccines do not offer effective protection against all the strains circulating in the region.



A High-Quality Solution Designed for Eastern Africa

The AgResults Foot and Mouth Disease Vaccine Challenge Project is an eight-year, USD\$17.34 million Pay-for-Results prize competition that supports the development, registration, and uptake of high-quality FMD vaccines tailored to meet the needs of Eastern Africa. Managed by GALVmed, the competition focuses on six target countries: Burundi, Ethiopia, Kenya, Rwanda, Tanzania, and Uganda. The prize is structured as a cost-share that reduces the cost-per-dose for buyers, enabling public and private sector actors to better combat FMD through access to more effective vaccines. In this way, the project encourages the widespread use of prophylactic vaccination to improve animal health and farmer livelihoods. The competition launched in February 2020 and will conclude in July 2028.



Project Objectives

Anticipated Impact



Develop and register high-quality FMD vaccines tailored to the needs of Eastern Africa



Incentivize manufacturers to support long-term efforts to control FMD in the Eastern African market with regionally appropriate vaccines



Create greater market stability and affordability through increased production and purchase of FMD vaccines that are regionally relevant



Increase access to and uptake of effective FMD vaccines



Build a private sector model for FMD vaccine purchase and distribution to complement public sector efforts



Reduce FMD-driven production losses for small-scale farmers in the region (estimated USD\$2.3 billion per year across sub-Saharan Africa)

Project Phases

Development Phase – In this phase, participating manufacturers work to develop an FMD vaccine that meets the following eligibility criteria:

- **Vaccine Development to Target Product Profile (TPP) Standards:** To ensure regional relevance, the quadrivalent vaccine must have a potency of at least 6PD50 and contain serotypes A, O, SAT1, and SAT2 that match circulating FMD viruses in Eastern Africa as demonstrated through serological testing against the Eastern African FMDV Reference Antigen Panel, developed by the Pirbright Institute, UK.
- **Vaccine Registration:** The manufacturer must achieve full registration in at least one target country.
- **Vaccine Approval:** The AgResults FMD Judging Panel must approve vaccines for competition entry that meet the competition's TPP and registration requirements.

Vaccine Distribution Cost-Share Phase

In this phase, the project uses a \$15.8 million cost-share mechanism to increase the distribution and adoption of high-quality FMD vaccines by funding a portion of the selling price of registered and approved vaccine(s). AgResults provides the cost-share funding to manufacturers on behalf of public and private sector buyers who purchase directly from the manufacturers, including the manufacturers' Local Technical Representative(s). Each sales period, the cost-share covers a percentage of the vaccine price for a fixed number of vaccine doses, as illustrated in the table below, totalling 12.5 million doses over the entirety of the Cost-Share Phase. The cost-share vaccine doses are allocated to the country(ies) where the approved vaccine(s) are registered.

The cost-share support is structured in three sales periods that run from October 2024 – July 2028:

Sales Period	# of Months	Start Date	Cost-Share Percentage*	Total Doses
1	18	1 Oct 2024	75%	3,000,000
2	14	1 Apr 2026	65%	4,250,000
3	14	1 Jun 2027	55%	5,250,000

*The AgResults cost-share percentage applies to a maximum vaccine price of USD\$2.00; if the vaccine has a selling price above USD\$2.00, the buyer will pay the difference.

Country Reserves: 60% of the total doses eligible for the cost-share in each sales period will be allocated to public sector buyers in the countries where the AgResults-approved vaccine is registered. The volume of doses allocated to each country will be announced on the Project website before each sales period.

Regional Pool: 40% of cost-share doses in each sales period will be allocated to the Regional Pool, which provides access to additional cost-share doses beyond the Country Reserves. The Regional Pool has two main components:

- Sector Agnostic Component: A portion of the pool available to both public and private sector buyers (65%)
- Private Sector Component: A portion of the pool available only to private sector buyers (35%)

Any buyer interested in purchasing the AgResults-approved FMD vaccines should contact the vaccine manufacturer directly and/or the manufacturer's in-country Local Technical Representative. Contact information is available on the Project's website (link below).



About AgResults

AgResults is a USD\$152 million collaborative initiative between the governments of Australia, Canada, the United Kingdom, and the United States, as well as the Gates Foundation and the World Bank that uses Pay-for-Results prize competitions to incentivize the private sector to overcome market barriers and develop solutions to food security and agricultural challenges that disproportionately affect people living in poverty. These competitions aim to reduce food insecurity, improve household nutrition and health, and strengthen food systems.

For more information about the AgResults FMD Vaccine Challenge Project, please email fmdchallenge@galvmed.org or visit the project website: <https://www.galvmed.org/foot-and-mouth-project/>